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Calcium oxalate kidney stones in patients on continuous ambulatory
peritoneal dialysis. Kidney stones were passed by ten out of 186 patients
with endstage renal disease who were treated with continuous ambula-
tory peritoneal dialysis (CAPD). Stones from seven patients were
examined by x-ray diffraction. In five of them the stones were com-
posed of calcium oxalate monohydrate. The urine calcium oxalate
activity product was determined in 44 CAPD patients, eight of whom
were stone formers, and compared to that of 120 normal volunteers. In
CAPD patients, mean urine ionic-calcium concentration was lower than
in normal subjects whereas mean urine ionic-oxalate concentration was
significantly higher than in normal subjects. In normal urine samples,
the calcium oxalate activity product showed a significant correlation
with both the urine ionic-calcium and the ionic-oxalate concentrations.
In contrast, in CAPD patients the calcium oxalate activity product
correlated with the ionic-calcium concentration but not with ionic-
oxalate. Although the urine ionic-calcium concentration is lower in
CAPD patients than in normal subjects, it is the relative increase in its
concentration which appears to be associated with the increased risk of
kidney stone formation in these patients. This relative hypercalciuria
seems to follow I ,25(OH)2 vitamin D3 administration.
Calculs rénaux d'oxalate de calcium chez des malades en dialyse
pêritonéale continue ambulatoire. Des calculs rénaux ont été éliminés
par dix de 186 malades avec une nephropathie terminale traitée par
dialyse péritonéale continue ambulatoire (CAPD). Les calculs de sept
malades ont été examines par diffraction aux rayons. Dans cinq d'entre
eux, les calculs étaient composes d'oxalate de calcium monohydraté.
Le produit d'activitC urinaire de l'oxalate de calcium a été déterminé
chez 44 malades en CAPD, dont huit étaient lithiasiques, et compares a
celui de 120 volontaires normaux. Chez les malades en CAPD, Ia
concentration urinaire moyenne en ions calcium était plus faible que
celle de sujets normaux, alors que la concentration moyenne en ion
oxalate était significativement plus élevée que chez les normaux. Dans
les échantillons urines normales, le produit d'activité de l'oxalate de
calcium indiquait une correlation significative avec les concentrations
unnaires d'ions calcium et d'ions oxalate. A l'opposé, chez les malades
en CAPD, le produit d'activité de l'oxalate de calcium était corrélé avec
La concentration d'ions calcium mais non d'ions oxalate. Bien que Ia
concentration urinaire d'ions calcium soit plus faible chez les malades
en CAPD que chez les sujets contrôles, c'est l'augmentation relative de
sa concentration qui semble être associée avec l'augmentation de
risques de formation calculeuse chez ces malades. Cette relative
hypercalciurie semble suivre l'administration de 1 ,25(OH)2D vitamine
D3.
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The spectrum of disturbances described in renal failure does
not appear to include nephrolithiasis. It is well known that
kidney stone formation usually ceases when recurrent stone
formers develop renal failure [1]. It was thought that the low
concentration of urinary calcium found in terminal renal failure
makes it highly unlikely that such patients would form kidney
stones. In recent years, however, several centers have reported
kidney stones in previously nonstone-forming dialysis patients
[2—5]. The present study reports the frequency and composition
of kidney stones observed in patients with terminal renal failure
treated with continuous ambulatory peritoneal dialysis (CAPD)
and highlights some of the factors responsible for their
formation.
Methods
During 1977 to 1981, 186 patients with endstage renal disease
were maintained on the Toronto Western Hospital (TWH)
CAPD program [6]. Ten out of these 186 patients developed
kidney stones while on CAPD. The stones from seven patients
were collected for crystallography and analyzed by x-ray dif-
fraction analysis (XRD), scanning electron microscopy (SEM),
and transmission electron microscopy (TEM) [7]. The presence
of protein matrix was studied chemically by the Lowry method
and inferred by the presence of a very broad band in the x-ray
diffraction patterns.
To further elucidate the pathogenesis of this complication, we
studied the composition of 24-hr urine samples from 44 of the
CAPD patients, including the stone formers, and 120 healthy
control subjects.
None of the stone formers had a history of nephrolithiasis
prior to dialysis; their initial diseases were: glomerulonephritis
(three patients), diabetic nephropathy (three patients), and
scleroderma, IgA-nephropathy, malignant hypertension, and
medullary cystic disease in one each. They developed stones
after being on CAPD from 6 to 9 months. Seven patients had
one or two episodes of stones and three as many as four. All
stones were passed spontaneously, some of them asymptomati-
cally and some after acute renal colic with hematuria and
dysuria with suprapubic discomfort. The episodes of renal colic
responded to symptomatic treatment.
The parameters measured were as follows: 24-hr urine for
calcium, oxalate, calcium oxalate (CaOx) activity product, as
534
-1--A _JLZ ri
Kidney stones in CAPD patients 535
Fig. 1. General appearance of stones passed by patients on CAPD. Fig. 2. Ultrastructure of CaOx stones on scanning electron microscope.
(>< 1200)
with the urine ionic calcium and ionic oxalate concentrations in
both CAPD patients and control subjects. Urine CaOx activity
product in CAPD patients was correlated with their serum Ca,
PTH, and dose of 1 ,25(OH)2 vitamin D3. Urine ionic Ca was also
correlated with the daily dose of 1 ,25(OH)2 vitamin D3. Simple
linear regression analysis was used for the above correlations
[17].
Results
Fig. 3. The CaOx crystals on transmission electron microscopy.
(x20,000)
well as serum calcium, and PTH measured on the same day.
Some of the patients had repeated investigations at 6-month
intervals.
The CaOx activity product in the urine was calculated with a
computer program designed by Robertson, Peacock, and Nor-
din [8], Robertson [91, and Robertson, Peacock, and Nordin
[10] using nine different individually measured constituents in
the urine (calcium, magnesium, sodium, potassium, ammoni-
urn, phosphate, oxalate, citrate, and sulfate) and pH measure-
ments. With this same program, we also calculated the concen-
trations of the ionic calcium (Ca) and oxalate (Ox) in the
urine.
Serum calcium was measured with an atomic absorption
spectrophotometer (model AA/l 20, Varian-Techtron, Spring-
vale, Australia) and corrected for total serum proteins [11].
Urinary oxalate was determined using a colorimetric method
[12, 13]. Plasma PTH was measured by a radioimmunoassay
which detects both the carboxy and amino terminals of the PTH
molecule [14].
Most of these patients took 1,25(OH)2 vitamin D3 by mouth to
control renal osteodystrophy [15, 16]. The mean dose per day
during the month preceding the investigation was calculated.
The calculated urine CaOx activity product was correlated
All the stones collected were very small, that is, less than 3
mm in size (Fig. 1). The stones produced by five of the seven
patients contained substantial amounts of Ca oxalate monohy-
drate (COM), (Ca C204 . H20) crystals, as demonstrated by x-
ray diffraction. The Ca oxalate crystals were mixed with protein
matrix in stones of two of these five patients. The amount of
matrix in stones of the three other patients was undetectable by
XRD, indicating that these stones contained very little organic
matrix. Of the remaining two patients, one had stones com-
posed of calcium apatite crystals while the other passed two
stones, one of which was composed of calcium oxalate mono-
hydrate and the other of matrix.
Ultrastructural studies showed that the COM stones were
composed of numerous small crystals of 1 to 3 m in size. As
can be seen by scanning electron microscopy (Fig. 2), these
crystals are exposed to the stone surfaces, in an apparently
unorganized manner. However, as shown by transmission
electron microscopy (Fig. 3), the crystals are actually stacked
up in a fairly orderly manner inside the COM stones.
The mean total 24-hr urinary calcium and oxalate excretions
in 44 CAPD patients and 120 normal volunteers are shown in
Table 1. Patients on CAPD excreted significantly less calcium,
oxalate, and urine volume per 24-hr than do normal control
subjects. The urine pH, however, did not differ significantly in
these two groups.
Table 2 shows the mean calculated urine ionic calcium and
oxalate concentrations in the CAPD patients and normal con-
trol subjects. The patients show significantly lower calcium but
higher ionic oxalate concentrations than the control subjects.
Figure 4 shows the values of the urine CaOx activity product
in the 44 CAPD patients and the 120 normal control subjects.
The "formation product" line separates the labile region, where
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CAPD patients(N = 44)
Normal subjects(N = 120) P value
Calcium, mmoieslday 0.2 0.2 4.1 2.1 < 0.0001
Oxalate, p.moies/day 120 90 350 150 < 0.0001
Volume, mi/day 335 280 1419 618 < 0.0001
pH 6.25 1.1 6.24 0.7 NS
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Fig. 4. Urine CaOx activity products in normal subjects and CAPD
patients, Circles surrounding closed circles indicate patients who
passed stones.
spontaneous crystallization or precipitation occurs, from the
metastable region, where nucleation does not occur under
normal circumstances [18]. It is interesting to note that the urine
of those CAPD patients forming stones had a product in the
labile region. The two stone patients whose CaOx activity
product was in the metastable region were the two with calcium
apatite and matrix stones.
The correlations between the calcium oxalate activity prod-
uct and the urinary ionic concentration of calcium and oxalate
in normal control subjects and CAPD patients are shown in
Figures 5 and 6, respectively. The values of the activity product
are expressed as the negative logarithm (to base 10). Thus, the
smaller the number, the greater the activity product. In normal
control subjects (Fig. 5), large increases in ionic calcium are
necessary but small increases in ionic oxalate concentrations
are sufficient to raise the activity product. In CAPD patients
(Fig. 6) on the other hand, the calcium oxalate activity product
increases with increasing ionic calcium concentration but is
independent of the ionic oxalate concentration, which is already
elevated.
The results of the correlation between urine CaOx activity
product and serum calcium, PTH and the daily dose of
1 ,25(OH)2 vitamin D3 in CAPD patients (Table 3) indicate that
the urinary calcium oxalate activity product shows a positive
CAPD patients(N = 44)
Normal s
(N = ubjects120) P value
Ca, mmoles/liter 0.48 0.4 1.59 0.9 < 0.0001
Ox, mmoles/liter 0.25 0.1 0.15 0.1 < 0.0001
correlation with serum calcium concentration, with the dosage
of 1,25(OH)2 vitamin D3 administered, and a negative correla-
tion with plasma PTH. There is also a significant (P <0.001)
positive correlation between the dosage of! ,25(OH)2 vitamin D3
and urinary ionic Ca.
Discussion
Kidney stone formation in ten of 186 CAPD patients (5.4%)
described in this study represents an unusually high incidence
of this disorder. To our knowledge, it must be considered a
previously unrecognized complication of this type of dialysis
treatment. In patients on chronic hemodialysis, the reported
incidence of stones varies from 5 to 22% [3, 4, 191.
To our knowledge, development of kidney stones in dialyzed
patients was reported first by Oreopoulos and Silverberg [2] in
1974. They described two patients, one on chronic peritoneal
and the other on chronic hemodialysis, who developed calcium
oxalate stones. Bommer et al [31 confirmed this observation,
that is, de novo formation of stones in a large percentage of
patients on chronic hemodialysis. These investigators in their
initial analysis found that the stones were composed of matrix,
but subsequent systematic sectioning of the stones confirmed
the presence of oxalate microcrystals [20]. Keiji and Kanichi [5]
described nine hemodialysis patients passing calcium oxalate
stones, while Carals et al [4] observed kidney stones among
7.5% of 160 patients on chronic hemodialysis. Koga et al [19]
using computerized tomography found a high incidence of
mineral-containing stones (51.1%). Our findings indicate, that
under certain conditions, which seem to be predominant in our
patients, the formation of calcium oxalate stones is enhanced,
whereas less frequently matrix or calcium apatite stones can
occur. Attention therefore was focused on the role of oxalic
acid and calcium.
Oxalic acid is an end product of amino acid and ascorbic acid
metabolism, normally excreted in the urine. Plasma oxalate
levels are elevated in uremic patients, from two to four times
the normal level, depending on the degree of renal failure and
the efficiency of dialysis [21, 24, 25]. Calcium oxalate deposi-
tion in several organs, such as the heart and the joints, has been
reported to be a complication' of chronic renal failure [22, 23,
26—29). Hautmann, Lehmann, and Komor [30], after measuring
the ionic calcium and oxalate concentrations in renal tissue
samples, suggested that their high concentrations in the human
papilla contribute to the formation of the calcium oxalate
deposits, which serve as the basis of stone formation.
The fact that increase in urine oxalate concentration in-
creases the risk of calcium oxalate crystal formation has been
recognized as one of the main causes of calcium oxalate stones
[31]. It has been shown that the degree of urine saturation of
calcium oxalate, expressed in terms of its corresponding activi-
ty product, is the most important single factor in the pathogene-
sis of kidney stones [32, 33] and depends on the ionic calcium
Table I. Total Ca and oxalate excretion in 24-hr urine (mean SD) in
CAPD patients and normal subjects
Table 2. Calculated urine ionic Ca and Ox" concentrations (mean
Sn) in CAPD patients and normal subjects
Normal
subjects
.
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Fig. 6. Correlation of urine CaOx activity product and urine ionic Ca(I) [r = 0.84, P < 0,00011 and ionic oxalate (0) [r = 0.02, P = 0.4]
concentrations in patients on CAPD. S.P. and F.P. denote solubility
product and formation product, respectively.
calcium concentrations only, but not with oxalate concentra-
tions. Thus, unlike normal people, CAPD patients show consis-
tently high urine-oxalate concentrations and have urinary CaOx
activity products which are more sensitive to changes in urine
calcium than are normal subjects but are independent of
changes in urine oxalate.
The fact that some of our normal control subjects have CaOx
activity product values greater than the formation product is
consistent with the theory that the kidney stone formation
depends not only on the activity of CaOx but also on the level of
urinary inhibitors of crystallization [35]. As has been shown
previously, patients with renal failure have significantly lower
values of inhibitors of calcification in urine, than do normal
subjects [361. It may be speculated that, in view of the consis-
tently high urine oxalate concentrations and decreased urinary
inhibitors of calcification in uremia, a relative increase in urine
calcium concentration is a major cause of kidney stone forma-
tion in our dialysis patients.
The positive correlation between urinary CaOx activity prod-
uct and serum calcium and between urinary CaOx activity
product and urine calcium, was to be expected. However, the
surprising negative correlation found between the urinary CaOx
activity product and plasma PTH level suggests that some other
factor might be responsible for the elevation of serum calcium
found in these patients. The highly significant correlation
between the dosage of 1 ,25(OH)2 vitamin D3 and urinary ionic
Ca and CaOx activity product levels supports the hypothesis
that treatment with l,25(OH)2 vitamin D3 played an important
role in the pathogenesis of kidney stones in our patients.
In conclusion, our CAPD patients demonstrated an increase
in urine calcium in response to treatment with l,25(OH)2
vitamin D3. In the presence of a consistently high urine-oxalate
concentration, a relative increase in urine calcium is responsi-
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Table 3. Correlation of urine CaOx activity product with serum
calcium, plasma PTH, and daily dose of 1 ,25(OH)2 vitamin D3
0.4
0.2
0
0
8.7 8.45 8.2 7.95 7.7 7.45 7.2 6.95
is..i (F.P.)
r P
CaOx vs. serum Ca +0.43 0.002
CaOx vs. plasma PTH —0.41 0.003
CaOx vs. daily dose of 1,25(OH)2 vitamin D3 +0.54 <0.004
and oxalate concentrations in the urine [18, 34]. As was shown
by Robertson and Nordin [18], the CaOx activity product can
be increased in normal subjects either by large increases in
urine calcium or small increases in urine oxalate concentra-
tions. Our findings in healthy volunteers confirm this
observation.
In this study, to our knowledge, we have shown for the first
time that in CAPD patients there is a significant correlation
between the levels of urinary CaOx activity product and urine
538 Oren eta!
ble for the rise in urinary calcium-oxalate activity product and
stone formation in some of these patients. The probability of
this adverse effect of 1 ,25(OH)2 vitamin D3 should be considered
when this drug is administered to dialysis patients who pass
urine.
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